Publications & Presentations

 

A sample of our Publications and Presentations:

Publications

  1. Cremaschi L, von Versen R, Benzing T, et al. Induction Therapy with Rabbit Antithymocyte Globulin versus Basilximab after Kidney Transplantation: A Health Economic Analysis from a German Perspective. Accepted for publication in Transplant International. June 1, 2017.
  2. Dombret H, Thomas X, Chevallier P, et al. Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review. Journal of Medical Economics. 2016. Also published online.
  3. Reitan JF, Kudrik FJ, Fox K, et al.  The Burden of Blood Transfusion:  A Utilization and Ecomonic Analysis- A Pilot Study in Patients with Chemotherapy-Induced Anemia (CIA) J Med Econ. 2013;16(5):1-6.
  4. Reitan JF, van Breda A, Corey-Lisle PK, et al.  Staff Time and Motion Assessment for Administration of Erythropoiesis-Stimulating Agents: A Two-Phase Pilot Study in Clinical Oncology PracticesClin Drug Investig. 2013. DOI 10.1007/s40261-013-0078-9.
  5. Reitan, JF, van Breda A, Shreay S, et al.  Erythropoiesis-Stimulating Agent (ESA) Practice Patterns in Patients With Chemotherapy-Induced Anemia (CIA) Treated at Hospital Oncology ClinicsHosp Pharm. 2013;48:120-26.
  6. Reitan J, Moleski R, van Breda A, et al.  Cost and Quality Implications of Opioid-Based Postsurgical Pain Control in Total Abdominal Hysterectomy: A Study of Cost Outliers and Opioid-Related Adverse EventsHosp Pharm. 2012;47:855-62.
  7. Adamson RT, Lew I, Beyzarov E, et al.  Clinical and Economic Impact of Intra- and Postoperative Use of Opioids and Analgesic Devices.  Hosp Pharm. 2011;46(supp):s1-s20.
  8. Griffith N, Allen C, Pultz A, Penza S.  The Impact of a Long-Acting Erythropoiesis Stimulating Protein on Patient Throughput in a Hospital-Based Ambulatory Oncology ClinicHosp Pharm.  2008;43:388–395.
  9. Beveridge, R., Rifkin, R., Moleski, R., et al. Impact of Long-Acting Growth Factors on Practice Dynamics and Patient Satisfaction. Pharmacotherapy. 2003;23(12 Part 2):101S-109S.
  10. Ueno W.  Costs of Outpatient Red Blood Cell TransfusionsJournal of Supportive Oncology. 2006:4:494-95.
  11. Milkovich G, Moleski R, Reitan J, et al.  Comparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive ChemotherapyPharmacotherapy. 2000;20:1432-40.

 

Presentations

  1. Plerixafor in Poor Mobilizers with Non-Hodgkin’s Lymphoma:  Multi-Center Time-Motion AnalysisAnnual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Marseille, France, March 2017.
  2. Induction Therapy with Rabbit Antithymocyte Globulin (rATG, Thymoglobulin®) vs Basilximab after Kidney Transplantation: A Health Economic Analysis from a German Perspective. 2016 British Transplant Society Annual Meeting, February 24, 2016, Glasgow, Scotland.
  3. Induction Therapy with Rabbit Antithymocyte Globulin (rATG, Thymoglobulin®) vs Basilximab after Kidney Transplantation: A Health Economic Analysis from a German Perspective. 2016 American Transplant Congress (ATC), June 13, 2016, Boston Massachusetts.
  4. Time and Cost of Hospitalisations for Salvage Therapy Among Adult Patients With Philadelphia (Ph)-Negative B-Cell Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (All) in Spain. ISPOR 19th Annual European Congress, Vienna, Austria, November 2, 2016.
  5. Quantification of the Time and Effort Associated with Autologous Peripheral Blood Stem Cell Mobilization : A European Perspective. ASH 57th Annual Meeting and Exposition, Orlando, Florida, December 2015.
  6. Hospitalisations Among Adult Patients With Ph-Negative B-Precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (All) Receiving Chemotherapy in Germany: A Retrospective Chart Review. ISPOR 18th Annual European Congress, Milan, Italy, November 2015.
  7. Healthcare Burden and Economic Cost of Hospitalisation During Chemotherapy for Adult Patients With Ph-Negative B-Precursor Relapsed or Refractory Acute Lymphoblastic Leukaemia in France: A Retrospective Chart Review.  ISPOR 18th Annual European Congress, Milan, Italy, November 2015.
  8. Retrospective Chart Review of Hospitalisations During Chemotherapy for Adult Patients With Ph-Negative B-Precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (All) in Italy.  ISPOR 18th Annual European Congress, Milan, Italy, November 2015.
  9. Health Economic Analysis of Rabbit Antithymocyte Globulin (Thymoglobulin) Versus Basiliximab in Renal Transplantation – a German Perspective at the American Society Nephrology (ASN) Kidney Week, 2015, San Diego, California, November 2015.
  10. Quantification of the Time and Effort Required for Autologous Peripheral Blood Stem Cell Collection: A European Perspective at the Annual Meeting of the German, Austrian and Swiss Associations of Hematology and Medical Oncology (DGHO), Basel, Germany, October 2015.
  11. Health Economic Analysis of Rabbit Antithymocyte Globulin (Thymoglobulin) Versus Basiliximab in Renal Transplantation – a German Perspective at the German Transplantation Society (DGT) 24th Annual Meeting, Dresden, Germany, October 2015.
  12. Quantification of the Time and Effort Required for Autologous Peripheral Blood Stem Cell Collection: A European Perspective. Annual meeting of the European Hematology Association (EHA), Milan, Italy, June 2014.
  13. Quantification of the Time and Efforts Required for Autologous Peripheral Blood Stem Cell Collection: A European Perspective. Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Milan, Italy, April 2014.
  14. Utilization Patterns of Erythropoiesis Stimulating Agents Prescribed for Chemotherapy-Induced Anemia, and the Impact of the Outpatient Regimen on Subsequent Inpatient Use: A Pilot Study.  ASHP Midyear, December 2010.
  15. Impact of Long- versus Short Acting Growth Factors on Staff Time Consumption and Utilization: A Multi-Center Study.  ASHP Annual Meeting, June 2006.
  16. Impact of a Long-Acting Erythropoietic Growth Factor on Practice Dynamics in an Oncology Clinic.  ASHP Midyear, December 2006.
  17. Time Burden of Blood Transfusion.  ASH, December 2005.
Copyright © 2017 RJM Group, LLC. All rights reserved. | Use & Privacy | Site Map | Admin